Defective repair of oxidative DNA damage in triple-negative breast cancer confers sensitivity to inhibition of poly(ADP-ribose) polymerase

Cancer Research

Volumn 69, Issue 8, 2009, Pages 3589-3596

  Alli, Elizabeth ^a   Sharma, Vandana B ^a   Sunderesakumar, Preethi ^a   Ford, James M ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE;

ANIMAL CELL; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER CELL CULTURE; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; ENZYME INHIBITION; EXCISION REPAIR; GENOMIC INSTABILITY; HUMAN; HUMAN CELL; NONHUMAN; ONCOGENE; OXIDATIVE STRESS; PRIORITY JOURNAL;

ANIMALS; BRCA1 PROTEIN; BREAST NEOPLASMS; CELL LINE, TUMOR; DNA DAMAGE; DNA GLYCOSYLASES; DNA REPAIR; GENES, BRCA1; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; OXIDATION-REDUCTION; POLY(ADP-RIBOSE) POLYMERASES;

EID: 65949124480     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-4016     Document Type: Article

References (49)

1. Perou CM, Sorlie T, Eisen MB. et al. Molecular portraits of human breast tumours. Nature 2000; 406: 747-52
2. Hu Z, Fan C, Oh DS. et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 2006; 7: 96. (Pubitemid 43786485)
3. Nielsen TO, Hsu FD, Jensen K. et al. Immunohisto-chemical and clinical characterization of the basal-like subtype of invasive breast carcinoma Clin. Cancer Res 2004; 10: 5367-74. (Pubitemid 39100473)
4. Sorlie T, Perou CM, Tibshirani R. et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. U S A 2001; 98: 10869-74. (Pubitemid 32878711)
5. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER) -negative, progesterone receptor (PR) -negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California Cancer Registry. Cancer 2007; 109: 1721-8. (Pubitemid 46668532)
6. Carey LA, Dees EC, Sawyer L. et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin. Cancer Res 2007; 13: 2329-34. (Pubitemid 46698581)
7. Dent R, Trudeau M, Pritchard KI. et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin. Cancer Res 2007; 13: 4429-34. (Pubitemid 47219710)
8. Haffty BG, Yang Q, Reiss M. et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J. Clin. Oncol 2006; 24: 5652-7. (Pubitemid 46631305)
9. Liedtke C, Mazouni C, Hess KR. et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J. Clin. Oncol 2008; 26: 1275-81.
10. Tischkowitz M, Brunet JS, Begin LR. et al. Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer 2007; 7: 134. (Pubitemid 47272190)
11. Sorlie T, Tibshirani R, Parker J. et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl. Acad. Sci. U S A 2003; 100: 8418-23. (Pubitemid 36842560)
12. Poulkes WD, Stefansson IM, Chappuis PO. et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J. Natl Cancer Inst 2003; 95: 1482-5. (Pubitemid 37279334)
13. Lakhani SR, Reis-Filho JS, Fulford L. et al. Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin. Cancer Res 2005; 11: 5175-80. (Pubitemid 41003703)
14. Turner NC, Reis-Filho JS. Basal-like breast cancer and the BRCA1 phenotype. Oncogene 2006; 25: 5846-53. (Pubitemid 44453440)
15. Rakha EA, Reis-Filho JS, Ellis IO. Basal-like breast cancer: a critical review. J. Clin. Oncol 2008; 26: 2568-81.
16. Zhang J, Powell SN, The role of the BRCA1 tumor suppressor in DNA double-strand break repair. Mol. Cancer Res 2005; 3: 531-9. (Pubitemid 41567272)
17. Hartman AR, Ford JM. BRCA1 induces DMA damage recognition factors and enhances nucleotide excision repair. Nat Genet 2002; 32: 180-4.
18. Farmer H, McCabe N, Lord CJ. et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434: 917-21. (Pubitemid 40559006)
19. Bryant HE, Schultz N, Thomas HD. et al. Specific killing of BRCA2-defieient tumours with inhibitors of poly (ADP-ribose) polymerase. Nature 2005; 434: 913-7. (Pubitemid 40559005)
20. Mortusewicz O, Ame JC, Schreiber V, Leonhardt H. Feedback-regulated poly (ADP-ribosyl) ation by PARP-1 is required for rapid response to DNA damage in living cells. Mucleic Acids Res 2007; 35: 7665-75.
21. Sgagias MK, Wagner KU, Hamik B. et al. Brcal -deficient murine mammary epithelial cells have increased sensitivity to CDDP and MMS. Cell Cycle 2004; 3: 1451-6. (Pubitemid 40310683)
22. Zhang J, Willers H, Feng Z. et al. Chk2 phosphorylation of BRCA1 regulates DMA double-strand break repair. Mol. Cell Biol. 2004; 24: 708-18. (Pubitemid 38057922)
23. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2 (-ΔΔC (T)) method. Methods 2001; 25: 402-8. (Pubitemid 34164012)
24. Collins A, Dusinska M, Franklin M. et al. Comet assay in human biomonitoring studies: reliability, validation, and applications. Environ Mol. Mutagen 1997; 30: 139-46. (Pubitemid 27440590)
25. Collins AR, Dusinska M, Gedik CM, Stetina R. Oxidative damage to DNA: do we have a reliable biomarker? Environ Health Perspect 1996;104 Suppl 3: 465-9. (Pubitemid 26197677)
26. Elstrodt F, Hollestelle A, Nagel JH. et al. BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants. Cancer Res 2006; 66: 41-5. (Pubitemid 43166006)
27. Gazdar AF, Kurvari V, Virmani A. et al. Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer. Int J. Cancer 1998; 78: 766-74. (Pubitemid 28530401)
28. Neve RM, Chin K, Fridlyand J. et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006; 10: 515-27.
29. Tomlinson GE, Chen TT, Stastny VA. et al. Characterization of a breast cancer cell line derived from a germ-line BRCA1 mutation carrier. Cancer Res 1998; 58: 3237-42. (Pubitemid 28371058)
30. Schagen FH, Moor AC, Cheong SC. et al. Photody-namic treatment of adenoviral vectors with visible light: an easy and convenient method for viral inactivation. Gene Ther. 1999; 6: 873-81. (Pubitemid 29243662)
31. Harper JW, Elledge SJ. The DNA damage response: ten years after. Mol. Cell 2007; 28: 739-45. (Pubitemid 350217064)
32. Hartman AR, Ford JM, BRCA1 and p53: compensatory roles in DNA repair. J. Mol. Med 2003; 81: 700-7. (Pubitemid 37491595)
33. Jackson AL, Loeb LA. The contribution of endogenous sources of DNA damage to the multiple mutations in cancer. Mutat Res 2001; 477: 7-21. (Pubitemid 32480184)
34. Klaunig JE, Kamendulis LM. The role of oxidative stress in carcinogenesis. Annu Rev Pharmacol Toxicol 2004; 44: 239-67. (Pubitemid 38263841)
35. Malins DC, Polissar NL, Gunselman SJ. Progression of human breast cancers to the metastatic state is linked to hydroxyl radical-induced DNA damage. Proc. Natl. Acad. Sci. U S A 1996; 93: 2557-63. (Pubitemid 26104386)
36. Storz P. Reactive oxygen species in tumor progression. Front Biosci 2005; 10: 1881-96. (Pubitemid 40529044)
37. Rodriguez H, Jaruga P, Leber D, Nyaga SG, Evans MK, Dizdaroglu M. Lymphoblasts of women with BRCA1 mutations are deficient in cellular repair of 8, 5'-cyclo-purine-2'-deoxynucleosides and 8-hydroxy- 2'-deoxygua-nosine. Biochemistry 2007; 46: 2488-96. (Pubitemid 46362422)
38. Crook T, Brooks LA, Crossland S. et al. p53 mutation with frequent novel condons but not a mutator phenotype in BRCA1- and BRCA2-associated breast tumours. Oncogene 1998; 17: 1681-9. (Pubitemid 28482645)
39. Lakhani SR, Van De Vijver MJ, Jacquemier J. et al. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J. Clin. Oncol 2002; 20: 2310-8. (Pubitemid 34441658)
40. Schuyer M, Berns EM. Is TP53 dysfunction required for BRCA1-associated carcinogenesis? Mol. Cell Endocrinol. 1999; 155: 143-52. (Pubitemid 29460973)
41. Achanta G, Huang P. Role of p53 in sensing oxidative DNA damage in response to reactive oxygen species-generating agents. Cancer Res 2004; 64: 6233-9. (Pubitemid 39129425)
42. Chatterjee A, Mambo E, Osada M, Upadhyay S, Sidransky D. The effect of p53-RNAi and p53 knockout on human 8-oxoguanine DNA glycosylase (hOggl) activity. FASEB J. 2006; 20: 112-4. (Pubitemid 43100484)
43. Offer H, Wolkowicz R, Matas D, Blumenstein S, Livneh Z, Rotter V. Direct involvement, of p53 in the base excision repair pathway of the DNA repair machinery. FEBS Lett 1999; 450: 197-204. (Pubitemid 29219514)
44. Seo YR, Fishel ML, Amundson S, Kelley MR, Smith ML. Implication of p53 in base excision DNA repair: in vivo evidence. Oncogene 2002; 21: 731-7. (Pubitemid 34146285)
45. Zhou J, Ahn J, Wilson SH, Prives C. A role for p53 in base excision repair. EMBO J. 2001; 20: 914-23. (Pubitemid 32167655)
46. Ashworth A. A synthetic lethal therapeutic approach: poly (ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J. Clin. Oncol 2008; 26: 3785-90.
47. Reardon JT, Bessho T, Kung HC, Bolton PH, Sancar A. In vitro repair of oxidative DNA damage by human nucleotide excision repair system: possible explanation for neurodegeneration in xeroderma pigmentosum patients. Proc. Natl. Acad. Sci. U S A 1997; 94: 9463-8. (Pubitemid 27357852)
48. Easton DF, Ford D, Bishop DT, Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J. Hum Genet 1995; 56: 265-71.
49. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE. Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet 1994; 343: 692-5. (Pubitemid 24087847)